CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

• Published in: Molecular psychiatry Vol. 18; no. 1; pp. 8 - 9
• Main Authors: Peñas-LLedó, E M, Trejo, H D, Dorado, P, Ortega, A, Jung, H, Alonso, E, Naranjo, M E G, López-López, M, LLerena, A
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.01.2013; Nature Publishing Group
• Subjects: 631/92/436/434; 692/699/476/1414; Adult and adolescent clinical studies; Amitriptyline; Amitriptyline - adverse effects; Amitriptyline - blood; Antidepressants; Antidepressive Agents - adverse effects; Antidepressive Agents - blood; Behavioral Sciences; Biological and medical sciences; Biological Psychology; Brain-derived neurotrophic factor; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Depression; Depressive Disorder, Major - blood; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - genetics; Dosage and administration; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Drug metabolism; Drug therapy; Female; Fluoxetine; Fluoxetine - adverse effects; Fluoxetine - blood; Follow-Up Studies; Humans; letter-to-the-editor; Letters to the editor; Major depressive disorder; Male; Medical sciences; Medicine; Medicine & Public Health; Memory; Metabolism; Mexico; Mood disorders; Neuropharmacology; Neurosciences; Pharmacology. Drug treatments; Pharmacotherapy; Physiology; Polymorphism, Genetic; Psychiatry; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Time Factors; Variance analysis; Mexico; Argentina; Mood disorder; Human; Amitriptyline; Serotonin; Fluoxetine; Psychotropic; Depression; Catecholamine; Tricyclic compound; Reuptake inhibitor; Metabolism; Selective serotonin reuptake inhibitor; Treatment; Neurotransmitter; Antidepressant agent; Early; Norepinephrine
• ISSN: 1359-4184; 1476-5578
• DOI: 10.1038/mp.2012.91